Elutia (NASDAQ:ELUT – Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, May 9th.
Elutia (NASDAQ:ELUT – Get Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.66) earnings per share (EPS) for the quarter. The business had revenue of $5.88 million during the quarter.
Elutia Stock Performance
Shares of NASDAQ ELUT traded down $0.05 during mid-day trading on Friday, hitting $2.80. The stock had a trading volume of 32,409 shares, compared to its average volume of 10,940. The company has a 50 day moving average of $3.13 and a two-hundred day moving average of $2.69. The firm has a market cap of $67.96 million, a PE ratio of -1.33 and a beta of 0.56. Elutia has a twelve month low of $1.10 and a twelve month high of $4.19.
About Elutia
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Recommended Stories
- Five stocks we like better than Elutia
- How to Calculate Options Profits
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Pros And Cons Of Monthly Dividend Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Investing in Commodities: What Are They? How to Invest in Them
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
